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Other factors being equal it might be  expected that  any specific 
immunological value of a given immune serum should be proportional 
to the amount of the specific antibody.  For example it might be held 
that  the  effectiveness of  a  given  antipneumococcus serum  in  pro- 
tecting animals against pneumococcus infection could be judged by 
estimating the amount of protein  specifically precipitable with the 
homologous capsular polysaccharide, that is, the amount of antibody 
protein  (precipitin).  This  thesis is presumably tenable only if  the 
injection of various animals with a single antigen gives rise to a single 
antibody, or to a mixture in fixed proportions of antibodies dominantly 
specific but differing in one or more chemical or immunological prop- 
erties.  Present evidence indicates that  agglutination, precipitation, 
and complement fixation are due to the same substances in the serum. 
It has not as yet been demonstrated, however, that in a single serum 
there exists only one antibody substance specific for a given antigen. 
This question is important  from the practical  as well as from the theoretical 
point of view.  The clinician has generally  held  to the significance of tests for 
potency in which animals  are used.  This view has  developed  as a  result of the 
fact that  antipneumococcus  sera  of certain  types afford  excellent  protection to 
the experimental  animal  and at  the same  time are effective therapeutic  agents 
in lobar pneumonia.  With other types of pneumococci, notably Type III, the 
immune sera may possess considerable antibody potency as judged by agglutina- 
tion titer and yet be lacking  in ability to protect animals  against  large numbers 
of pneumococci.  Sera of  these  types  have  also  proven  less successful  in  the 
clinic. 
On the other  hand, it has long  been  recognized  that  evaluation  by  animal 
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methods is difficult  and simpler means of potency estimations have been sought. 
In  spite  of  many  excellent  studies on this  subject  (1-6),  it  is as  yet  by  no 
means  certain  that  an  absolute  parallelism  exists  between  in vitro and in vivo 
results.  It is  generally held  that this  uncertainty  is related to the  lack of pre- 
cise methods for determining protective potency. 
The  present  paper  consists  of  an  experimental  appraisal  of  the 
mouse protection test, its quantitative possibilities, and of the relation 
between  the  amount  of  antibody  quantitatively  determined  by  in 
vitro methods  and  the  amount  of demonstrable  protective  antibody. 
EXPERIMENTAL 
These experiments deal only with Type I  antipneumococcus sera. 
Sera.--Type  I  antipneumococcus  horse  sera  were  obtained  through  the 
courtesy of Dr.  Augustus  B. Wadsworth  of the New York State Department  of 
Health  and  Dr.  W.  E.  Bunney of the  Michigan State  Department  of  Health. 
The standard serum used  is that  designated  as 425  and  has  been  described  by 
Kirkbride,  Hendry,  and  Murdick  (7).  According  to  titrations  carried  out by 
these workers this serum contains 1000 mouse protective  units  per  cc.  by com- 
parison  with  the  National  Institute  of Health  standard  serum.  Type I  anti- 
pneumococcus rabbit sera were produced in this laboratory. 
Capsular Polysaccharide.--Viscous  Type  I  capsular  polysaccharide  was  pre- 
pared by the method of Heidelberger, Kendall, and Scherp (8).  Analyses of this 
preparation showed nitrogen 5.58 per cent; acetyl 7.35 per cent; and ash calculated 
as sodium 3.98 per cent.  In 0.1 per cent solution in 0.85 per cent NaCI the poly- 
saccharide had a  relative viscosity of 1.22)  For the preparation of stock solu- 
tions  the polysaccharide was dried  to constant  weight at  low temperature  and 
dissolved  in  saline  (containing merthiolate  1-10,000).  This  solution  was  then 
diluted to give a final polysaccharide concentration of 0.1 per cent. 
Determination of Specifically Precipitable Nitrogen.--Specific  precipitates  were 
prepared from the various sera studied by the addition to them of varying amounts 
of the  capsular  polysaccharide.  The method of Heidelberger  and  Kendall  (9) 
was followed and  all precipitates  were prepared  in the  cold and  washed  twice 
with  ice-cold  saline.  In  every  instance  increasing  amounts  of polysaccharide 
were added to constant amounts of serum and the total volume of each reacting 
mixture was kept constant by the addition of cold saline.  The specific  precipi- 
tates  were  digested  and  their  nitrogen  content  determined  by  the  gasometric 
micro method of Van Slyke (10) as modified by Kirk, Page, and Van Slyke (11). 
The precise details of the application of this method have been previously de- 
scribed (12).  Duplicate precipitates were prepared and consequently the figures 
given for precipitated nitrogen in the various tables are the mean of two deter- 
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minations unless otherwise indicated.  Aliquots of the initial supernatant  solu- 
tions  decanted  from the  precipitates  after  the  first  centrifugation  were  tested 
separately for the presence of uncombined polysaccharide and uncombined anti- 
body.  In each instance the same serum was used for these tests as had been used 
in the formation of the initial precipitates.  In this way it was possible to deter- 
mine the position of the equivalence zone for each serum. 
Inasmuch as the precipitates were prepared from constant amounts of serum 
in each instance and since the volume of the reacting mixtures was kept constant, 
there was no appreciable variation in the concentration of lipids in the individual 
preparations.  From the results  of previous work it  is  therefore assumed  that 
the amount of lipid adsorbed by each precipitate within any single experiment was 
constant.  Consequently it has not been necessary to make any correction for the 
very small amount of lipid nitrogen in the precipitates  since this  would be ex- 
pected to be constant for any particular serum. 
Culture.--Pneumococcus Type I, original Neufeld strain.  The culture is main- 
rained in rabbit blood broth at 37°C. with transfers every 2nd day.  Under these 
conditions the virulence of the culture remains practically constant, that is, there 
is an almost constant number of virulent organisms in a given volume of a culture 
of a given age.  The virulence is such that 0.000,000,01  cc. of culture given intra- 
peritoneally, produces a fatal infection in mice.  This amount of culture usually 
represents 3 microorganisms. 
Mice.--Throughout this  work the so called Rockefeller strain of white mice 
has been used.  This  stock is highly inbred  and the host factors involved are 
fairly well  understood.  All protection  tests  have  been  carried  out  with  mice 
weighing from 17 to 23 gm. 
Mouse Protection  Test.--Tests  for  the  protective  potencies  of  the 
various sera were carried out by the method  described by Kirkbride, 
Hendry,  and Murdick  (7)  and the results  analyzed by the method  of 
Muench (cited by Lloyd, Theiler, and Ricci (13)). 
This protection method differs  from certain others in general use by the fact 
that  a  relatively large amount of culture  is  used  as infective inoculum.  This 
amount of culture is so chosen as to avoid the Schwdlenwert and yet be in the 
range in which the titer limit follows roughly the law of multiple proportions (14). 
In order to determine the value of the unknown serum a simultaneous titration is 
carded out with a  serum of known potency which serves as a standard for com- 
parison.  In practice the following technical procedure has been observed. 
1.  The culture is diluted in broth so that 0.5 cc. of the dilution contains 0.1 cc. 
of the original 18 hour blood broth culture.  (This amount of culture contains 
approximately  30,000,000  pneumococci aud  in  this  instance  represents  a  cor- 
responding number of miuimum lethal doses).  The usual virulence controls are 
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2.  At least three different dilutions of each serum are used in each test.  The 
sera are progressively diluted  X  2,  the  precise dilutions being determined  by 
exploratory tests. 
3.  For the actual test at least 5 mice are injected with each combination of 
serum and culture.  Each mouse receives 0.5 cc. culture dilution and 0.5 cc. of the 
appropriate serum dilution, these being mixed in the syringe and injected into the 
peritoneal cavity. 
4.  Mice surviving for 96 hours are considered as protected by the corresponding 
amount of serum. 
Estimation of Protective Potencies 
The most difficult feature of any method involving biological variables is the 
accurate  evaluation  of  the  results  obtained.  Various  workers  have  adopted 
various end-points.  Thus  the  minimum  amount  of  serum  which  will protect 
60 per cent of mice can be taken as the end-point.  There are three objections 
to  this and similar criteria.  First, this method gives end-points which are as 
widely spaced as are the dilutions of serum, that is, only rough approximations of 
possible numerical  values  can  be  obtained.  Secondly,  the  result  is  actually 
dependent  on  very few mice,  those in  the group receiving the particular pro- 
tecting dilution and those of the group receiving the next lower amount of serum. 
Thirdly, results are not always sufficiently regular to permit an adequate deter- 
mination  of  the  end-point.  Thus,  with  5  or  even  10  mice per dilution, two 
amounts of serum, one being twice the other, may result in the same percentage 
survival.  Several attempts have  been made  to overcome this  end-point diffi- 
culty.  It seemed very desirable to obtain a  sensitive numerical end-point based 
not on the small group of mice at any particular dilution level but rather one 
which would take into account  the fate of all mice irrespective of the amount 
of serum. 
Since the usual data, if plotted, give curves with much sharper slopes in  the 
region of 50 per cent survival, it must be generally agreed that in this type of 
biological work this is the only logical end-point.  After several different methods 
had been tried the so called Muench 50 per cent end-point accumulation method 
was adopted. 
This method was devised by Dr. Hugo Muench of The Rockefeller Foundation 
and is extremely simple in application.  It has been used in the analysis of the 
results of protection tests in yellow fever work by Lloyd, Theiler, and Ricci (13) 
and in studies on the titration of vaccine virus by Parker and Rivers (15).  The 
latter authors discuss the validity of the method and the system used for obtain- 
ing the numerical end-point.  In brief, the method is as follows: The survivals 
and deaths for each serum dilution are separated.  The figures in each column 
are then  accumulated, each column being added beginning at the smaller end. 
If the resulting figures are then plotted against serum dilutions the lines will cross 
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about a survival rate of 50 per cent.  Actually it is unnecessary to plot these data 
since a simple calculation  will provide  the figure. 
An illustration  of the actual application  of this method is provided in Table I. 
It will be noted that in this titration 10 mice have been used for each dilution  of 
serum.  The results  in terms of percentage  survival for each dilution  are shown 
in column 4.  When these figures are directly plotted a line connecting them forms 
a smooth curve and the 50 per cent end-point is easily determined.  Results  of 
this order are,  however,  very exceptional.  In the fifth and sixth  columns  the 
survivals and deaths have been accumulated  as described above.  The percentage 
survival of each serum level has been calculated  and is shown in column 7.  On 
inspection  it is obvious that the desired  50 per cent end-point  lies between  the 
serum dilutions  1-40 and 1-80.  The exact point is obviously 23/46 or 0.50 of the 
distance  between  1-40  and  1-80.  Since the progression  in  serum  dilutions  is 
geometric it is necessary either to convert the basic dilution  number (40 in this 
TABLE  I 
Specimen  Mouse  Protection  Test  with  Determination  of 50  Per  Cent  End-Point 
by the Muenck Accumulation  Method 
Ser  tim 
dilution 
1-10 
1-20 
1-40 
1-80 
1-160 
Result 
Survived 
10 
9 
7 
3 
1 
Died  Survival 
per cent 
0  IO0 
1  9O 
3  7O 
7  3O 
9  10 
Accumulation 
LrvivaIs 
30 
20 
11 
4 
1 
Deaths 
0 
1 
4 
11 
20 
Survivals 
per cent 
100 
95 
73 
27 
5 
Calculated 
50 per cent 
end-point 
1-56 
instance)  into a  log factor for multiplication,  or much simpler  in 
convert the factor 0.50 into a proportional  factor by reference to 
chart.  The calculated  end-point in this example is 1-56. 
operation,  to 
a progression 
For  the  actual  estimation  of  the  potency of  a  given  serum  it  is 
necessary  to  carry out  protection  titrations  of  the  unknown  serum 
and of the standard serum at the same time.  This requirement tends 
to overcome the disadvantages of slight variations in the number of 
microorganisms  in  a  culture  from  day  to  day.  The  end-point  for 
each  serum  is  then  determined  and  by proportional calculation  the 
potency of  the  unknown  serum  can  be  estimated.  An  example  of 
actual  titrations  on  the  same  serum  at  different  times  is  given  in 
Table  II.  Five  independent  titrations  of  an  unknown  serum  have 418  ANTIPNEUMOCOCCUS  SERA.  I 
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been  carried  out  simultaneously  with  titrations  of  the  known  or 
standard serum. 
The data presented in Table II are fairly representative of the order of results 
generally obtained.  Some of these titrations would present an impossible problem 
were it necessary to judge the end-points on a simple survival basis.  Furthermore 
the results show the great advantages of simultaneous titrations of unknown and 
standard for although the actual end-points for each serum vary widely the varia- 
tions are generally in the same direction for both sera at the same time.  Thus 
when  the actual unitage value is calculated one finds a  rather dose agreement 
considering the number of mice used in each titration.  It is believed that the 
TABLE  III 
Mouse Protective  Potencies and Specifically  Precipitable  Antibody  of Nine Type I 
Antipneumococcus  Horse Sera 
Group  Serum 
lot 
A  58 
57 
50 
14 
B  49 
59 
60 
AA 
13 
Character 
Raw, single 
Raw, single 
Raw, pooled 
Concentrated 
Raw, pooled 
Raw, single 
Raw, single 
Raw, pooled 
Concentrated 
Protective 
units per co. 
440 
550 
760 
3145 
500 
870 
1000 
1405 
61~ 
Maximum 
specifically 
preclpitsble 
nitrogen 
rag. per c~. 
O. 765 
1.018 
1.510 
5. 798 
0.645 
1.081 
1. 229 
1.844 
7.125 
Protective 
units per mg. 
of specifically 
precipltable 
nitrogen 
575 
540 
505 
545 
775 
805 
815 
760 
855 
Meltn 
protective ratio 
for each 
group 
540 
800 
mean value, 1405 protective units per cc., is as representative of the actual pro- 
tective potency of the serum as any figure obtainable by any biological method. 
The probable error involved in titrations such as that illustrated with five separate 
determinations is about 10 per cent although no accurate estimate of this factor 
can be made without much longer series of titrations. 
Antibody Content of Type I Antipneumococcus Horse Sera 
With a measure of validity having been shown for the method of 
estimation of protective potencies and for the analysis of the results 
it is now possible to proceed to a comparison of the protective potency 
and the amount of specific antibody (precipitin) demonstrable in vitro. 420  ANTIPNEUMOCOCCUS  SEILk.  I 
These two forms of experimental analysis  have  been carried out on 
nine Type I  antipneumococcus horse sera and the results are shown 
in Table III. 
For the estimation of mouse protective potencies several titrations were carried 
out with each serum,  the average number in this series being slightly over 4. 
The average number of mice per serum, exclusive of those involved in the simul- 
taneous titration of the standard serum, was 73.  These repeated titrations were 
necessary in order to secure numerical end-points with some degree of precision. 
Similarly the estimations of maximum specifically precipitable nitrogen represent 
data secured from complete precipitin curves, each point on which represents an 
average of determinations on two duplicate precipitates. 
The  nine  antipneumococcus horse  sera  included  in  Table  III  fall 
into  two  groups  dependent  upon  the  number  of  mouse  protective 
units per rag. of specifically precipitable nitrogen  (hereinafter termed 
the protective ratio).  Thus group  A  includes four sera, both raw and 
concentrated, with potencies ranging from 440 to 3145  units per cc. 
of serum.  In the number of units per rag. of specifically precipitable 
nitrogen (protective ratios) however, these sera differ but slightly, the 
range being from 505 to 575 with a mean of 540 units per rag. 
In  contrast  are  the  results with  the  sera  of  group  B.  Although 
the mouse protective potencies of these sera range from 500 to 6100 
units per  cc.,  the  protective ratios  are  rather  uniform ranging from 
760 to 855 units per rag. with a mean value of 800. 
It is perhaps merely fortuitous that the mean protective ratios of 
these two groups of Type I  antipneumococcus horse sera stand in the 
approximate  relation of 2:3.  It  does not seem likely however that 
the actual protective ratios of the various sera are matters of chance. 
The difference between the results of the two groups is considerably 
greater than  the outside probability of error in  either protection or 
nitrogen estimations. 
Several possible sources of error do, however, exist.  The validity of the mouse 
protection titrations has already been discussed, and while some allowance must 
be made for the probability of error in each instance, this possible deviation is not 
sufficiently great to account for the differences between the two groups.  A second 
possibility is that the amounts of specifically precipitable nitrogen do not accur- 
ately represent  the amounts of specific antibody.  These determinations were, 
however,  very carefully carried out and the results of extensive checking  show 
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of specifically precipitable nitrogen as determined by the standard procedure is a 
fixed  characteristic  of a  given serum.  Whether  one is  warranted  in  assuming 
that this precipitahle nitrogen represents only specific antibody is another matter. 
It has been shown by Heidelberger and Kendall (16), for example, that if Type II 
capsular polysaccharide is added to a serum containing both Type I and Type II 
antibodies,  both  will be found in  the  resulting precipitates.  An example of a 
quantitative  experiment  designed  to  determine  the  extent  of this  non-specific 
precipitation is shown in Table IV.  Type I  capsular polysaccharide was added 
to Type I and Type II sera separately and after these had been mixed.  It will be 
noted that while the addition of Type I  capsular polysaccharide to the Type II 
serum gave no precipitate the addition of the carbohydrate to the mixture of the 
two sera gave a nitrogen result higher by 7.2 per cent than was obtained by the 
addition of the polysaccharide to the Type I  serum.  This is regarded as a  sig- 
TABLE  IV 
The Influence of Heterologous Antibodies on the  Apparent  Amount of Specifically 
Precipitable Nitrogen 
Type I  antipneumococcus Type II  antipneumococcu,~  Type I  capsular 
horse  serum  horse  serum  polysaccharide  Prccipltable  nitrogen 
~C.  ~C.  trig.  rag. 
1.0  --  0.25  1.490 
1.0  1.0  0.25  1.597 
--  1.0  0.25  0.000 
Precipitation carried out at 4°C. according to the method of Heidelberger and 
Kendall (9). 
nificant increase but the amount is not great enough even under the conditions of 
this experiment to affect seriously the general results shown in Table IIL 
Antibodies other than the type specific anticarbohydrate are present in prac- 
tic.ally every Type I antipneumococcus horse serum.  Some of these, such as those 
directed against the pneumococcus protein and the somatic carbohydrate (C sub- 
stance) are present in amounts so small as to affect the results only to a very slight 
extent even were a  considerable proportion included in the immune precipitate. 
Tests as to the monovalence of the immune horse sera were carried out and it was 
found that only one, No. 58, gave any reaction with the capsular polysaccharides 
of other pneumococcus types; this serum had antibodies which reacted with the 
capsular  polysaccharide  of Type II Pneumococcus, although  the  reaction was 
faint.  It would therefore  appear  that  the  quantitative  results  have not been 
seriously affected by non-specific reactions. 
Since  there  appears  to be no  obvious experimental  error  sufficient 
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immune  horse  sera  another  explanation  must  be  sought.  In  the 
absence of definitive evidence any explanation must, however, be of a 
hypothetical nature. 
As a  first possibihty it may be that certain of these sera contain substances 
other than  the specific antibody which largely condition the in vivo efficacy of 
these antibodies.  From the results of studies on the relation of lipids to immuno- 
logical reactions, one might hold that an abnormal lipid pattern would tend to 
inhibit the protective action of the serum (17).  This possibility seems somewhat 
unlikely, however, in view of the fact that each group included both pooled sera 
and  sera  from  single  bleedings.  Furthermore  if  some  inhibitor  were  present 
in the sera of group A it would seem unlikely that the amount would be so con- 
stant  with respect to the amount  of precipitable antibody as to give the con- 
TABLE  V 
Mouse Protective Potencies and Specifically  Precipitable Antibody of Seven Type I 
Antipneumococcus Rabbit Sera 
Maximum specifi-  Protective units  Mean protective 
Serum lot  Protective units  rally precipitable  per rag. of specifically  ratio 
per cc.  mtrogen  precipitable  nitrogen 
22 
28 
27 
A7 
26 
25 
24 
1070 
1130 
1190 
1270 
1390 
1830 
1910 
rag. per co. 
0.938 
0.986 
1.108 
1.128 
1.116 
1.533 
1.510 
1140 
1145 
1075 
1125 
1245 
1195 
1265 
1170 
All lots represent pooled bleedings and the sera have not been concentrated. 
sistent  results  obtained.  If  the  inhibitor  were  intimately and  quantitatively 
associated with the antibody molecules this hypothesis might be tenable. 
A  second explanation is that  certain horses may produce antibodies having 
greater protective values.  Here again the matter of sera from single and pooled 
bleedings would seem to make this possibility slight. 
A  third possibility is that the antibodies in a  given immune horse serum, al- 
though reacting with the specific polysaccharide, may in fact represent a  series 
of substances possessing different avidities, different degrees of specificity, differ- 
ent  protective values,  and  perhaps  even  different  chemical properties.  It  is 
possible that an immune serum may contain a mixture of specifically reactive anti- 
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Antibody Content of Antipneumococcus Rabbit Sere 
Determinations  of protective potencies and of maximum amounts 
of specifically precipitable nitrogen have been carried out with seven 
Type  I  antipneumococcus  rabbit  sera.  The  results  of  these  deter- 
minations are presented in Table V. 
The estimations of protective potencies are based on an average of 4.7 titra- 
tions per serum, with an average number of 77 mice per serum, exclusive of those 
involved in the simultaneous titration of the standard serum. 
It will  be  noted  that  the  protective values of the  immune  rabbit 
sera range  from  1070  to  19i0  units  per  cc.  but  that  the  number of 
protective  units  per  mg.  of  specifically  precipitable  nitrogen  is  rel- 
atively  constant,  averaging  1170.  Thus  Type  I  antipneumococcus 
rabbit  sera  appear  to  be  uniform  in  their  protective  ratios.  This 
result  stands  in  contrast  to  those  obtained  with  antipneumococcus 
horse sera. 
There is reason therefore to believe that in the case of immune rabbit serum 
the  protective potency can  be  directly  estimated from determinations  of the 
maximum amount of specifically precipitable protein.  This, however, is true only 
under certain definite conditions.  It has been clearly pointed  out  by  Heidel- 
berger, Kendall, and Scherp (8) that various preparations of capsular polysacchar- 
ide vary in their capacity to precipitate the antibodies of antipneumococcus rabbit 
serum.  This variation is so great that it is necessary to test each polysaccharide 
preparation.  It is believed, however, that if a given polysaccharide preparation 
is standardized against one serum and if this serum has been fully appraised in a 
mouse protection test, one should be able to standardize all other immune rabbit 
sera of the same type on the basis of the known precipitating properties of the 
given lot of polysaccharide. It is known, for example, that the lot of polysacchar- 
ide used in these experiments will precipitate approximately 92 per cent of the 
specific protective antibody from a given antipneumococcus rabbit serum. 
The general differences  between the protective ratios of immune horse and 
immune rabbit sera can perhaps be partially explained.  With Bauer (18) it has 
been shown by ultrafiltration that the horse antibodies are in general larger than 
those of immune rabbit serum.  Heidelberger and Pedersen  (19) have demon- 
strated similar differences by the use of the ultracentrifuge.  Although in certain 
details the results by the two methods are not in complete accord, there is now 
little doubt but that a  difference  in size  does exist.  If the rabbit antibody is 
actually smaller than that of the horse there should be in a given mass of rabbit 
antibody a much greater reactive surface and therefore one would expect that a 424  ANTIPNEU~OCOCCUS  SERA.  X 
greater amount of carbohydrate could be bound in proportion  to the amount of 
antibody.  At the present time it is not possible to conclude that this explanation 
accounts  for the observed differences in protective ratios, but the facts are sug- 
gestive. 
SUMMARY 
The  ability  to  carry  out  with  some  measure  of  precision  mouse 
protection  tests for the  estimation of potency of antipneumococcus 
sera has made possible the correlation of the protective potency with 
the  amount  of  specifically  precipitable  protein.  With  antipneu- 
mococcus rabbit  sera  these protective  ratios  are  relatively constant 
and  higher  than  those  with  immune  horse  serum.  Type  I  anti- 
pneumococcus horse sera, on the other hand, show no such constancy 
but fall into two groups;  and there  is  as yet no  simple method for 
determining to which group a serum belongs. 
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